Local News

• Implant Sciences amends Security Purchase Agreement with Laurus  Implant Sciences announced that on September 30, 2008, the Company and LV Administrative Services entered into an amendment, effective as of September 29, 2008, to the Securities Purchase Agreement dated as of September 29, 2005 between the Company and Laurus.
  Implant Sciences Corporation October 03, 2008  
• Critical Therapeutics announces effectiveness of registration statement for merger  Critical Therapeutics announced that the Securities and Exchange Commission has declared effective its Registration Statement on Form S-4 containing the Proxy Statement/Prospectus relating to the proposed merger between Critical Therapeutics and Cornerstone BioPharma Holdings.
  Critical Therapeutics, Inc. October 03, 2008  
• Oscient Pharmaceuticals receives NASDAQ notice  Oscient Pharmaceuticals received notification from the Listings Qualifications Department of The NASDAQ Stock Market that, as of October 2, 2008, the Company's market value of publicly held shares had closed below the minimum $15 million threshold set forth in Marketplace Rule 4450(b)(3).
  Oscient Pharmaceuticals Corporation October 03, 2008  
• Biogen Idec may shift headquarters to Weston  Biogen Idec, one of the state's largest biotechnology companies, is considering moving its corporate headquarters from Cambridge to Weston, which would add it to a growing list of Cambridge biotechs that have jumped to the suburbs because of lower rents and more options for office space.
  The Boston Globe October 03, 2008  Todd Wallack
• Lilly and Deciphera Pharmaceuticals announce licensing and collaboration agreement  Eli Lilly and Company and privately-held Deciphera Pharmaceuticals announced that the two companies have entered into a collaboration and worldwide licensing agreement related to Deciphera's preclinical B-Raf kinase inhibitor program for the study of potential oncology therapeutics.
  Eli Lilly and Company October 03, 2008  
• Genentech, Glycart and Roche enter into collaboration for potential cancer therapy  Genentech, GlycArt, a company wholly-owned by Roche, and Roche have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt's GA101 molecule.
  Genentech, Inc. October 02, 2008  
• Abiomed confirms revenue guidance for fiscal year 2009  Abiomed confirmed its fiscal year 2009 revenue guidance of $75 - 80 million. Abiomed will be announcing financial results for the second quarter of fiscal 2009 during the first full week of November.
  Abiomed, Inc. October 02, 2008  
• Monsanto increases 2008 earnings-per-share guidance  Monsanto Company raised its fiscal year 2008 earnings-per-share (EPS) guidance again, citing a strong conclusion to the fiscal year from its Roundup and other glyphosate-related herbicide business paired with the previously announced better-than-anticipated seeds-and-traits performance.
  Monsanto Company October 02, 2008  
• Monsanto completes sale of POSILAC bovine somatotropin and related business  Monsanto announced that it has completed the sale of its POSILAC(R) bovine somatotropin brand and related business to Eli Lilly and Company. Lilly purchased assets and liabilities of Monsanto associated with the POSILAC brand and related business for an upfront payment of $300 million.
  Monsanto Company October 02, 2008  
• NeuroMetrix receives FDA 510(k) clearance for UNIVERSAL(TM) electrodes  NeuroMetrix announced that it has received 510(k) clearance for its UNIVERSAL Electrodes from the U.S. Food and Drug Administration (FDA). This regulatory determination by the FDA gives NeuroMetrix clearance to market the UNIVERSAL Electrodes in the U.S.
  NeuroMetrix, Inc. October 02, 2008  

   (next 10 articles)